Insusense Therapeutics website launches

News

Come meet us at DK Bio 2019

20. February 2019

7-11 January 2019: Meet Insusense Therapeutics in San Francisco at this year’s JP Morgan biotech conference

7. January 2019

Paul Little, Operating Partner in Lundbeckfonden Emerge, replaces Christian Elling as CEO of Insusense Therapeutics

1. October 2018

Lundbeck Foundation doubles its investment in Aarhus-based Insusense Therapeutics

20. October 2015

About Us

InsuSence Therapeutics is a product-focused biotechnology company based on novel breakthrough science in diabetes biology, which has the potential to quantum leap to important new Type 2 diabetes therapeutics.